Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
JoVE Journal
Biology

A subscription to JoVE is required to view this content. Sign in or start your free trial.

Bacterial Delivery of RNAi Effectors
 
Click here for the English version

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Article DOI: 10.3791/2099-v 07:57 min August 18th, 2010
August 18th, 2010

Chapters

Summary

Please note that all translations are automatically generated.

Click here for the English version.

For development of RNA interference (RNAi)-based therapies, a novel strategy was developed, transkingdom RNAi (tkRNAi). This technology uses non-pathogenic bacteria to produce and deliver therapeutic short hairpin RNA (shRNA) into target cells. Here, tkRNAi was successfully applied for reversal of classical ABCB1-mediated multidrug resistance (MDR) of cancer cells.

Tags

RNA Interference RNAi Effectors Transkingdom RNAi Therapeutic Utilization RNAi-mediating Agents Escherichia Coli Short Hairpin RNA (shRNA) TRIP Vector Yersinia Pseudotuberculosis Invasin β1-integrin-positive Mammalian Cells Listeria Monocytogenes Listeriolysin O T7 RNA Polymerase ABCB1 (MDR1/P-glycoprotein)
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter